Small cell lung carcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- Small cell lung cancer (SCLC) is a highly aggressive malignant neoplasm, accounting for 10-15% of lung cancer cases, characterized byrapid growth, and early metastasis. SCLC usually manifests as a large hilar mass with bulky mediastinal lymphadenopathy presenting clinically with chest pain, persistent cough, dyspnea, wheezing, hoarseness, hemoptysis, loss of appetite, weight loss, and neurological and endocrine paraneoplastic syndromes. SCLC is primarily reported in elderly people with a history of long-term tobacco exposure.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Small cell lung carcinoma
- Therapeutic area
- Oncology
- small cell lung carcinoma
- SCLC
- oat cell carcinoma
- oat cell carcinoma (morphologic abnormality)
- poorly differentiated endocrine neoplasm
- Small cell lung cancer
- lung oat cell carcinoma
- lung small cell carcinoma
- lung small cell neuroendocrine carcinoma
- oat cell carcinoma of lung
- oat cell carcinoma of the lung
- oat cell lung carcinoma
- small cell cancer of the lung, somatic
- small cell carcinoma of lung
- small cell carcinoma of the lung
- small cell lung cancer
- small cell neuroendocrine carcinoma of lung
- small cell neuroendocrine carcinoma of the lung
- small-cell cancer of lung
- SCLC1
- Severity
- Severe
- Endocrinology
- Oncology
- Pulmonology
- MONDO ID
- MONDO:0008433
- Parent condition
- MONDO:0000402
Related records
Broader conditions (27)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine gland neoplasm
- Endocrine system disorder
- Epithelial neoplasm
- Human disease
- Lower respiratory tract disorder
- Lung cancer
- Lung carcinoma
- Lung disorder
- Lung neoplasm
- Lung neuroendocrine neoplasm
- Malignant endocrine neoplasm
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
Narrower conditions (3)
- Combined small cell lung carcinoma
- Lung combined type small cell adenocarcinoma
- Occult small cell lung carcinoma
Trials (1,262)
- [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
- 11C Topotecan PET Imaging
- 13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
- 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
- A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
- A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
- A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
- A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Approved drugs (7)
- Atezolizumab
- Durvalumab
- Etoposide
- Lurbinectedin
- Tarlatamab
- Topotecan hydrochloride
- Trilaciclib dihydrochloride
Drugs in development (228)
- 7-ethyl-10-hydroxycamptothecin Phase 2
- Acetazolamide Phase 1
- Adavosertib Phase 2
- Adebrelimab Phase 3
- Afatinib Phase 2
- Aflibercept Phase 2
- AK-01 Phase 1
- Aldoxorubicin Phase 2
- Alisertib Phase 2
- Allopurinol Phase 1
- AMG-404 Phase 1
- Amrubicin Phase 3
- Amrubicin hydrochloride Phase 3
- Amuvatinib Phase 2
- Antineoplaston A10 Phase 2
- Arsenic trioxide Phase 2
- Atigotatug Phase 2
- Auranofin Phase 1
- Avelumab Phase 2
- Becatecarin Phase 2
Other linked drugs (3)
- INCB-059872
- Lithium
- Mecapegfilgrastim